In Vivo delivery systems for therapeutic genome editing

International Journal of Molecular Sciences

Volumn 17, Issue 5, 2016, Pages

  Wang, Luyao ^a   Li, Fangfei ^a   Dang, Lei ^a   Liang, Chao ^a   Wang, Chao ^a   He, Bing ^a   Liu, Jin ^a   Li, Defang ^a   Wu, Xiaohao ^a   Xu, Xuegong ^b   Lu, Aiping ^a   Zhang, Ge ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b Zhengzhou Hospital of Traditional Chinese Medicine   (China)

Author keywords

Genome editing; In vivo delivery systems; Programmable nucleases; Vectors

Indexed keywords

ADENOVIRUS VECTOR; BACULOVIRUS VECTOR; CELL PENETRATING PEPTIDE; LENTIVIRUS VECTOR; LIPOSOME; NUCLEASE; PARVOVIRUS VECTOR; POLYMER; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; ZINC FINGER NUCLEASE; ZINC FINGER PROTEIN;

CONJUGATE; CRISPR CAS SYSTEM; CRISPR CAS9 SYSTEM; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; GENE CASSETTE; GENE DELIVERY SYSTEM; GENE MUTATION; GENE SEQUENCE; GENE VECTOR; HUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; VIRAL GENE DELIVERY SYSTEM; ADENOVIRIDAE; DNA REPAIR; GENE EDITING; GENETICS; LENTIVIRINAE; METABOLISM;

ADENOVIRIDAE; CRISPR-CAS SYSTEMS; DNA REPAIR; GENE EDITING; GENETIC VECTORS; LENTIVIRUS; TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES; ZINC FINGERS;

EID: 84974622888     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17050626     Document Type: Review

References (110)

1. Cox, D.B.; Platt, R.J.; Zhang, F. Therapeutic genome editing: Prospects and challenges. Nat. Med. 2015, 21, 121-131
2. Perez-Pinera, P.; Ousterout, D.G.; Gersbach, C.A. Advances in targeted genome editing. Curr. Opin. Chem. Biol. 2012, 16, 268-277
3. Kim, Y.G.; Cha, J.; Chandrasegaran, S. Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. USA 1996, 93, 1156-1160
4. Miller, J.C.; Tan, S.; Qiao, G.; Barlow, K.A.; Wang, J.; Xia, D.F.; Meng, X.; Paschon, D.E.; Leung, E.; Hinkley, S.J.; et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 2011, 29, 143-148
5. Cho, S.W.; Kim, S.; Kim, J.M.; Kim, J.S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 2013, 31, 230-232
6. Wells, D. Gene Therapy Progress and Prospects: Electroporation and other Physical Methods. Nat. Rev. 2004, 11, 1363-1369
7. Thomas, C.E.; Ehrhardt, A.; Kay, M.A. Progress and problems with the use of viral vectors for gene therapy. Nature reviews. Genetics 2003, 4, 346-358
8. Yin, H.; Kanasty, R.L.; Eltoukhy, A.A.; Vegas, A.J.; Dorkin, J.R.; Anderson, D.G. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014, 15, 541-555
9. Van Dommelen, S.M.; Vader, P.; Lakhal, S.; Kooijmans, S.A.; van Solinge, W.W.; Wood, M.J.; Schiffelers, R.M. Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery. J. Control. Release 2012, 161, 635-644
10. Vannucci, L.; Lai, M.; Chiuppesi, F.; Ceccherini-Nelli, L.; Pistello, M. Viral vectors: A look back and ahead on gene transfer technology. New Microbiol. 2013, 36, 1-22
11. Bessis, N.; GarciaCozar, F.J.; Boissier, M.C. Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther. 2004, 11, S10-S17
12. Baum, C.; Kustikova, O.; Modlich, U.; Li, Z.; Fehse, B. Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors. Hum. Gene Ther. 2006, 17, 253-263
13. Vectors Used in Gene Therapy Clinical Trials. Available online: http://www.wiley.com//legacy/wileychi/genmed/clinical (accessed on July 2015).
14. Sun, C.Y.; Shen, S.; Xu, C.F.; Li, H.J.; Liu, Y.; Cao, Z.T.; Yang, X.Z.; Xia, J.X.; Wang, J. Tumor Acidity-Sensitive Polymeric Vector for Active Targeted siRNA Delivery. J. Am. Chem. Soc. 2015, 137, 15217-15224
15. Hsu, P.D.; Lander, E.S.; Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157, 1262-1278
16. Ul Ain, Q.; Chung, J.Y.; Kim, Y.H. Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. J. Control. Release 2015, 205, 120-127
17. Bibikova, M.; Beumer, K.; Trautman, J.K.; Carroll, D. Enhancing Gene Targeting with Designed Zinc Finger Nucleases. Science 2003, 300, 764
18. Zhang, Z.; Zhang, S.; Huang, X.; Orwig, K.E.; Sheng, Y. Rapid assembly of customized TALENs into multiple delivery systems. PLoS ONE 2013, 8, e80281
19. Urnov, F.D.; Miller, J.C.; Lee, Y.L.; Beausejour, C.M.; Rock, J.M.; Augustus, S.; Jamieson, A.C.; Porteus, M.H.; Gregory, P.D.; Holmes, M.C. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005, 435, 646-651
20. Thierry, A.; Dujon, B. Nested chromosomal fragmentation in yeast using the meganuclease I-Sce I: A new method for physical mapping of eukaryotic genomes. Nucleic Acids Res. 1992, 20, 5625-5631
21. Chevalier, B.S.; Stoddard, B.L. Homing endonucleases: Structural and functional insight into the catalysts of intron/intein mobility. Nucleic Acids Res. 2001, 29, 3757-3774
22. Smith, J.; Grizot, S.; Arnould, S.; Duclert, A.; Epinat, J.C.; Chames, P.; Prieto, J.; Redondo, P.; Blanco, F.J.; Bravo, J.; et al. A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res. 2006, 34, e149
23. Galetto, R.; Duchateau, P.; Pâques, F. Targeted approaches for gene therapy and the emergence of engineered meganucleases. Expert Opin. Biol. Ther. 2015, 9, 1289-1306
24. Chames, P.; Epinat, J.C.; Guillier, S.; Patin, A.; Lacroix, E.; Pâques, F. In vivo selection of engineered homing endonucleases using double-strand break induced homologous recombination. Nucleic Acids Res. 2005, 33, e178
25. Chapdelaine, P.; Pichavant, C.; Rousseau, J.; Pâques, F.; Tremblay, J.P. Meganucleases can restore the reading frame of a mutated dystrophin. Gene Ther. 2010, 17, 846-858
26. Gouble, A.; Smith, J.; Bruneau, S.; Perez, C.; Guyot, V.; Cabaniols, J.-P.; Leduc, S.; Fiette, L.; Av’e, P.; Micheau, B.; et al. Efficient in toto targeted recombination inmouse liver by meganuclease-induced double-strand break. J. Gene Med. 2006, 8, 616-622
27. Izmiryan, A.; Basmaciogullari, S.; Henry, A.; Paques, F.; Danos, O. Efficient gene targeting mediated by a lentiviral vector-associated meganuclease. Nucleic Acids Res. 2011, 39, 7610-7619
28. Urnov, F.D.; Rebar, E.J.; Holmes, M.C.; Zhang, H.S.; Gregory, P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. 2010, 11, 636-643
29. Kim, H.; Kim, J.-S. A guide to genome engineering with programmable nucleases. Nat. Rev. Genet. 2014, 15, 321-334
30. Blaese, R.M.; Culver, K.W.; Miller, A.D.; Carter, C.S.; Fleisher, T.; Clerici, M.; Shearer, G.; Chang, L.; Chiang, Y.; Tolstoshev, P.; et al. T Lymphocyte-Directed Gene Therapy for ADASCID: Initial Trial Results after 4 Years. Science 1995, 270, 475-480
31. Giacca, M.; Zacchigna, S. Virus-mediated gene delivery for human gene therapy. J. Control. Release 2012, 161, 377-388
32. Bergmann, T.; Schulz, E.; Ehrhardt, A. Progress and Problems with Viral Vectors for Delivery of TALENs. J. Mol. Genet. Med. 2014, 8, 1-7
33. Campos, S.K.; Barry, M.A. Current Advances and Future Challenges in Adenoviral Vector Biology and Targeting. Curr. Gene Ther. 2007, 7, 189-204
34. Cannon, P.; June, C. Chemokine receptor 5 knockout strategies. Curr. Opin. HIV AIDS 2011, 6, 74-79
35. Huang, S.; Kamihira, M. Development of hybrid viral vectors for gene therapy. Biotechnol. Adv. 2013, 31, 208-223
36. Thomas, C.E.; Ehrhardt, A.; Kay, M.A. Progress and Problems with the Use of Viral Vectors for Gene Therapy. Nat. Rev. 2003, 4, 346-359
37. Matrai, J.; Chuah, M.K.; VandenDriessche, T. Recent advances in lentiviral vector development and applications. Mol. Ther. 2010, 18, 477-490
38. Lombardo, A.; Genovese, P.; Beausejour, C.M.; Colleoni, S.; Lee, Y.L.; Kim, K.A.; Ando, D.; Urnov, F.D.; Galli, C.; Gregory, P.D.; et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 2007, 25, 1298-1306
39. Apolonia, L.; Waddington, S.N.; Fernandes, C.; Ward, N.J.; Bouma, G.; Blundell, M.P.; Thrasher, A.J.; Collins, M.K.; Philpott, N.J. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol. Ther. 2007, 15, 1947-1954
40. Gellhaus, K.; Cornu, T.I.; Heilbronn, R.; Cathomen, T. Fate of Recombinant Adeno-Associated Viral Vector Genomes during DNA Double-Strand Break-Induced Gene Targeting in Human Cells. Hum. Gene Ther. 2010, 21, 543-553
41. Ellis, B.L.; Hirsch, M.L.; Porter, S.N.; Samulski, R.J.; Porteus, M.H. Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration- approved drugs. Nat. Ther. 2013, 20, 35-42
42. Anguela, X.M.; Sharma, R.; Doyon, Y.; Miller, J.C.; Li, H.; Haurigot, V.; Rohde, M.E.; Wong, S.Y.; Davidson, R.J.; Zhou, S.; et al. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood J. 2013, 122, 3283-3287
43. Händel, E.M.; Gellhaus, K.; Khan, K.; Bednarski, C.; Cornu, T.I.; Müller-Lerch, F.; Kotin, R.M.; Heilbronn, R.; Cathomen, T. Versatile and Efficient Genome Editing in Human Cells by Combining Zinc-Finger Nucleases with Adeno-Associated Viral Vectors. Hum. Gene Ther. 2012, 23, 321-329
44. Rahman, S.H.; Bobis-Wozowicz, S.; Chatterjee, D.; Gellhaus, K.; Pars, K.; Heilbronn, R.; Jacobs, R.; Cathomen, T. The Nontoxic Cell Cycle Modulator Indirubin Augments Transduction of Adeno-Associated Viral Vectors and Zinc-Finger Nuclease-Mediated Gene Targeting. Hum. Gene Ther. 2013, 24, 67-77
45. Michael, J.; Metzger, A.M.-S.; Stoddard, B.L.; Miller, A.D. Single-strand nicks induce homologous recombination with less toxicity than double-strand breaks using an AAV vector template. Nucleic Acids Res. 2011, 39, 926-935.
46. Hojun, L.; Harigot, V.; Doyon, Y.; Li, J.; Bhagwat, A.; Wong, S.; Anguela, X.; Sharma, R.; Ivanciu, L.; Murphy, S.M.; et al. LBA-5 Phenotypic Correction of a Mouse Model of Hemophilia B by in vivo Genetic Correction of F9 Gene. In Proceedings of the American Society of Hematology Annual Meeting, San Diego, CA, USA, 10-13 December 2010.
47. Philip, L.; Felgener, T.R.G.; Holm, M.; Roman, R.; Chen, H.W.; Wenz, M.; Northrop, J.P.; Ringold, G.M.; Dsnielsen, M. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 1987, 84, 7413-7417.
48. Almofti, M.R.; Harashima, H.; Shinohara, Y.; Almofti, A.; Baba, Y.; Kiwada, H. Cationic liposome-mediated gene delivery: Biophysical study and mechanism of internalization. Arch. Biochem. Biophys. 2003, 410, 246-253
49. Perez, E.E.; Wang, J.B.; Miller, J.C.; Jouvenot, Y.; Kim, K.A.; Liu, O.; Wang, N.; Lee, G.; Bartsevich, V.V.; Lee, Y.; et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biothechnol. 2008, 26, 808-817
50. Wong, A.W.; Baginski, T.K.; Reilly, D.E. Reilly, Enhancement of DNA Uptake in FUT8-Deleted CHO Cells for Transient Production of Afucosylated Antibodies. Biotechnol. Bioeng. 2010, 106, 751-763
51. Gaj, T.; Guo, J.; Kato, Y.; Sirk, S.J.; Barbas, C.F., 3rd. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Methods 2012, 9, 805-812
52. Kim, S.; Kim, D.; Cho, S.W.; Kim, J.; Kim, J. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014, 24, 1012-1019
53. Ramakrishna, S.; Kim, Y.H.; Kim, H. Stability of Zinc Finger Nuclease Protein Is Enhanced by the Proteasome Inhibitor MG132. PLoS ONE 2013, 8, e54282
54. Jo, Y.I.; Kim, H.; Ramakrishna, S. Recent developments and clinical studies utilizing engineered zinc finger nuclease technology. Cell. Mol. Life Sci. 2015, 72, 3819-3830
55. Li, H.; Haurigot, V.; Doyon, Y.; Li, T.; Wong, S.Y.; Bhagwat, A.S.; Malani, N.; Anguela, X.M.; Sharma, R.; Ivanciu, L.; et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011, 475, 217-224
56. Mussolino, C.; Morbitzer, R.; Lütge, F.; Dannemann, N.; Lahaye, T.; Cathomen, T. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 2011, 39, 9283-9293
57. Zhu, H.; Lau, C.H.; Goh, S.L.; Liang, Q.; Chen, C.; Du, S.; Phang, R.Z.; Tay, F.C.; Tan, W.K.; Li, Z.; et al. Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells. Nucleic Acids Res. 2013, 41, e180
58. Cai, M.; Yang, Y. Targeted Genome Editing Tools for Disease Modeling and Gene Therapy. Curr. Gene Ther. 2014, 14, 2-9
59. Nelson, C.E.; Hakim, C.H.; Ousterout, D.G.; Thakore, P.I.; Moreb, E.A.; Rivera, R.M.C.; Zhang, F.; Madhavan, S.; Duan, D.; Ousterout, D.G.; et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2016, 351, 403-407
60. Holkers, M.; de Vries, A.A.F.; Gonçalves, M.A.F.V. Nonspaced inverted DNA repeats are preferential targets for homology-directed gene repair in mammalian cells. Nucleic Acids Res. 2012, 40, 1984-1999
61. Holkers, M.; Maggio, I.; Liu, J.; Janssen, J.M.; Miselli, F.; Mussolino, C.; Recchia, A.; Cathomen, T.; Gonçalves, M.A. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res. 2012, 41, e63
62. Hu, Z.; Ding, W.; Zhu, D.; Yu, L.; Jiang, X.; Wang, X.; Zhang, C.; Wang, L.; Ji, T.; Liu, D.; et al. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J. Clin. Investig. 2015, 125, 425-537
63. Ru, R.; Yao, Y.; Yu, S.; Yin, B.; Xu, W.; Zhao, S.; Qin, L.; Chen, X. Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs. Cell Regen. 2013, 2, 5
64. Liu, J.; Gaj, T.; Patterson, J.T.; Sirk, S.J.; Barbas, C.F. Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS ONE 2014, 9, e85755
65. Wiedenheft, B.; Sternberg, S.H.; Doudna, J.A. RNA-guided genetic silencing systems in bacteria and archaea. Nat. Rev. 2012, 482, 331-339
66. Peter, C.; Fineran, E.C. Memory of viral infections by CRISPR-Cas adaptive immune systems: Acquisition of new information. Virology 2012, 434, 202-209.
67. Barrangou, R.; Fremaux, C.; Deveau, H.; Richards, M.; Boyaval, P.; Moineau, S.; Romero, D.A.; Horvath, P. CRISPR Provides Acquired Resistance against Viruses in Prokaryotes. Sci. Rep. 2007, 315, 23-28
68. Horvath, P.; Barrangou, R. CRISPR/Cas, the Immune System of Bacteria and Archaea. Science 2010, 327, 167-172
69. Makarova, K.S.; Aravind, L.; Grishin, N.V.; Rogozin, I.B.; Koonin, E.V. A DNA repair system specific for thermophilic Archaea and bacteria predicted by genomic context analysis. Nucleic Acids Res. 2002, 30, 482-496
70. Heidenreich, M.; Zhang, F. Applications of CRISPR-Cas system in neuroscience. Nat. Rev. Neurosci. 2015, 17, 36-44
71. Ran, F.A.; Cong, L.; Yan, W.X.; Scott, D.A.; Gootenberg, J.S.; Kriz, A.J.; Zetsche, B.; Shalem, O.; Wu, X.; Makarova, K.S.; et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015, 520, 186-191
72. Swiech, L.; Heidenreich, M.; Banerjee, A.; Habib, N.; Li, Y.; Trombetta, J.; Sur, M.; Zhang, F. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 2015, 33, 102-106
73. Tabebordbar, M.; Zhu, K.; Cheng, J.K.; Chew, W.L.; Widrick, J.J.; Yan, W.X.; Maesner, C.; Wu, E.Y.; Xiao, R.; Ran, F.A.; et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 2016, 351, 407-411
74. Long, C.; Amoasii, L.; Mireault, A.A.; McAnally, J.R.; Li, H.; Sanchez-Ortiz, E.; Bhattacharyya, S.; Shelton, J.M.; Bassel-Duby, R.; Olson, E.N. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 2016, 351, 400-403
75. Lai, Y.; Yue, Y.; Liu, M.; Ghosh, A.; Engelhardt, J.F.; Chamberlain, J.S.; Duan, D. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol. 2005, 23, 1435-1439
76. Murlidharan, G.; Samulski, R.J.; Asokan, A. Biology of adeno-associated viral vectors in the central nervous system. Front. Mol. Neurosci. 2014, 7, 76-85
77. Platt, R.J.; Chen, S.; Zhou, Y.; Yim, M.J.; Swiech, L.; Kempton, H.R.; Dahlman, J.E.; Parnas, O.; Eisenhaure, T.M.; Jovanovic, M.; et al. CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling. Cell 2014, 159, 440-455
78. Senis, E.; Fatouros, C.; Grosse, S.; Wiedtke, E.; Niopek, D.; Mueller, A.K.; Borner, K.; Grimm, D. CRISPR/Cas9-mediated genome engineering: An adeno-associated viral (AAV) vector toolbox. Biotechnol. J. 2014, 9, 1402-1412
79. Kennedy, E.M.; Kornepati, A.V.; Mefferd, A.L.; Marshall, J.B.; Tsai, K.; Bogerd, H.P.; Cullen, B.R. Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic. Methods 2015, 91, 82-86
80. Cheng, R.; Peng, J.; Yan, Y.; Cao, P.; Wang, J.; Qiu, C.; Tang, L.; Liu, D.; Tang, L.; Jin, J.; et al. Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9. FEBS Lett. 2014, 588, 3954-3958
81. Zuris, J.A.; Thompson, D.B.; Shu, Y.; Guilinger, J.P.; Bessen, J.L.; Hu, J.H.; Maeder, M.L.; Joung, J.K.; Chen, Z.Y.; Liu, D.R. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 2015, 33, 73-80
82. Wightman, L.; Kircheis, R.; Rössler, V.; Carotta, S.; Ruzicka, R.; Kursa, M.; Wagner, E. Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J. Gene Med. 2011, 3, 362-372
83. Zuckermann, M.; Hovestadt, V.; Knobbe-Thomsen, C.B.; Zapatka, M.; Northcott, P.A.; Schramm, K.; Belic, J.; Jones, D.T.; Tschida, B.; Moriarity, B.; et al. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat. Commun. 2015, 6, 7391-7400
84. Li, L.; He, Z.Y.; Wei, X.W.; Gao, G.P.; Wei, Y.Q. Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors. Hum. Gene Ther. 2015, 26, 452-462
85. Alvarez, R.D.; Sill, M.W.; Davidson, S.A.; Muller, C.Y.; Bender, D.P.; DeBernardo, R.L.; Behbakht, K.; Huh, W.K. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI- cholesterol lipopolymer in the treatment of persistent of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A gynecologic oncology group study. Gynecol. Oncol. 2014, 3, 571-577
86. Ramakrishna, S.; Kwaku Dad, A.B.; Beloor, J.; Gopalappa, R.; Lee, S.K.; Kim, H. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 2014, 24, 1020-1027
87. Yin, H.; Song, C.Q.; Dorkin, J.R.; Zhu, L.J.; Li, Y.; Wu, Q.; Park, A.; Yang, J.; Suresh, S.; Bizhanova, A.; et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 2016, 34, 328-333
88. Findlay, G.M.; Boyle, E.A.; Hause, R.J.; Klein, J.C.; Shendure, J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 2014, 513, 120-123
89. Yin, H.; Xue, W.; Chen, S.; Bogorad, R.L.; Benedetti, E.; Grompe, M.; Koteliansky, V.; Sharp, P.A.; Jacks, T.; Anderson, D.G. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 2014, 32, 551-553
90. Xue, W.; Chen, S.; Yin, H.; Tammela, T.; Papagiannakopoulos, T.; Joshi, N.S.; Cai, W.; Yang, G.; Bronson, R.; Crowley, D.G. CRISPR-mediated directmutation of cancer genes in themouse liver. Nature 2014, 514, 380-396
91. Jo, Y.I.; Suresh, B.; Kim, H.; Ramakrishna, S. CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods. Biochim. Biophys. Acta 2015, 1856, 234-243
92. Rieder, F.; Steininger, C. Cytomegalovirus vaccine: Phase II clinical trial results. Clin. Microbiol. Infect. 2013, 20, 95-103
93. Kim, J.S.; Lee, H.J.; Carroll, D. Genome editing with modularly assembled zinc-finger nucleases. Nat. Methods 2010, 7, 91
94. Kim, Y.; Kweon, J.; Kim, A.; Chon, J.K.; Yoo, J.Y.; Kim, H.J.; Kim, S.; Lee, C.; Jeong, E.; Chung, E.; et al. A library of TAL effector nucleases spanning the human genome. Nat. Biotechnol. 2013, 31, 251-258
95. Cornu, T.I.; Thibodeau-Beganny, S.; Guhl, E.; Alwin, S.; Eichtinger, M.; Joung, J.K.; Cathomen, T. DNA-binding Specificity Is a Major Determinant of the Activity and Toxicity of Zinc-finger Nucleases. Mol. Ther. 2008, 16, 352-358
96. Maggio, I.; Holkers, M.; Liu, J.; Janssen, J.M.; Chen, X.; Gonçalves, M.A.F.V. Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Sci. Rep. 2014, 4, 1-11
97. Shalem, O.; Sanjana, N.E.; Hartenian, E.; Shi, X.; Scott, D.A.; Mikkelsen, T.S.; Heckl, D.; Ebert, B.L.; Root, D.E.; Doench, J.G.; et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014, 343, 84-89
98. Wang, T.; Wei, J.J.; Sabatini, D.M.; Lander, E.S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 2014, 343, 80-86
99. McNeer, N.A.; Anandalingam, K.; Fields, R.J.; Caputo, C.; Kopic, S.; Gupta, A.; Quijano, E.; Polikoff, L.; Kong, Y.; Bahal, R.; et al. Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium. Nat. Commun. 2015, 6, 6952
100. Tasciotti, E.; Liu, X.; Bhavane, R.; Plant, K.; Leonard, A.D.; Price, B.K.; Cheng, M.M.; Decuzzi, P.; Tour, J.M.; Robertson, F.; et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 2008, 3, 151-157
101. Liu, C.H.; Yu, S.Y. Cationic nanoemulsions as non-viral vectors for plasmid DNA delivery. Colloids Surf. B Biointerfaces 2010, 79, 509-515
102. He, Z.Y.; Wei, X.W.; Luo, M.; Luo, S.T.; Yang, Y.; Yu, Y.Y.; Chen, Y.; Ma, C.C.; Liang, X.; Guo, F.C. Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts. J. Control. Release 2013, 172, 679-689
103. Cho, S.W.; Kim, S.; Kim, Y.; Kweon, J.; Kim, H.S.; Bae, S.; Kim, J. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 2014, 24, 132-141
104. Francisco Martín, K.B.; Cobo, M.; Muñoz, P.; Anderson, P.; Toscano, M.G. New Vectors for Stable and Safe Gene Modification. Gene Therapy-Developments and Future Perspectives; InTech: Rijeka, Croatia, 2011; pp. 1-29. ISBN: 978-953-307-617-1.
105. Klein, T.; Loschberger, A.; Proppert, S.; Wolter, S.; van de Linde, S.; Sauer, M. Live-cell dSTORM with SNAP-tag fusion proteins. Nat. Methods 2011, 8, 7-9
106. Tebas, P.; Stein, D.; Tang, W.W.; Frank, I.; Wang, S.Q.; Lee, G.; Spratt, S.K.; Surosky, R.T.; Giedlin, M.A.; Nichol, G.; et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 2014, 370, 901-910
107. Kim, H.J.; Lee, H.J.; Kim, H.; Cho, S.W.; Kim, J.S. Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res. 2009, 19, 1279-1288
108. Kim, Y.; Kweon, J.; Kim, J.S. TALENs and ZFNs are associated with different mutation signatures. Nat. Methods 2013, 10, 185
109. Burnett, J.C.; Zaia, J.A.; Rossi, J.J. Creating genetic resistance to HIV. Curr. Opin. Immunol. 2012, 24, 625-632
110. Qasim, W.; Amrolia, P.J.; Samarasinghe, S.; Ghorashian, S.; Zhan, H.; Stafford, S.; Butler, K.; Ahsan, G.; Gilmour, K.; Adams, S.; et al. First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL. Blood 2015, 126, 2046